FY2025 EPS Estimates for TG Therapeutics, Inc. Increased by Analyst (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating) – Research analysts at B. Riley increased their FY2025 earnings estimates for shares of TG Therapeutics in a report released on Thursday, November 10th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings per share of $0.39 for the year, up from their prior estimate of $0.35. The consensus estimate for TG Therapeutics’ current full-year earnings is ($1.44) per share.

Separately, StockNews.com initiated coverage on TG Therapeutics in a research report on Wednesday, October 12th. They issued a “sell” rating for the company. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $21.25.

TG Therapeutics Stock Up 10.8 %

Shares of NASDAQ TGTX opened at $9.34 on Monday. The stock has a fifty day moving average price of $6.13 and a 200 day moving average price of $5.98. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.53. TG Therapeutics has a 12-month low of $3.48 and a 12-month high of $33.44. The company has a market cap of $1.36 billion, a P/E ratio of -5.28 and a beta of 2.12.

Institutional Trading of TG Therapeutics

Several large investors have recently modified their holdings of TGTX. State Street Corp lifted its stake in shares of TG Therapeutics by 47.8% in the second quarter. State Street Corp now owns 14,235,263 shares of the biopharmaceutical company’s stock worth $60,500,000 after acquiring an additional 4,606,679 shares in the last quarter. Vanguard Group Inc. raised its position in shares of TG Therapeutics by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 12,130,963 shares of the biopharmaceutical company’s stock valued at $115,366,000 after purchasing an additional 39,526 shares in the last quarter. BlackRock Inc. boosted its stake in shares of TG Therapeutics by 0.4% during the 1st quarter. BlackRock Inc. now owns 8,935,578 shares of the biopharmaceutical company’s stock valued at $84,978,000 after buying an additional 33,413 shares during the last quarter. Maverick Capital Ltd. grew its position in shares of TG Therapeutics by 10.7% during the first quarter. Maverick Capital Ltd. now owns 6,677,726 shares of the biopharmaceutical company’s stock worth $63,505,000 after buying an additional 642,851 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of TG Therapeutics in the second quarter worth $11,379,000. 72.64% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

(Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

Read More

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.